Lv3
235 积分 2025-07-22 加入
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
2个月前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
2个月前
已完结
Comparative efectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity‑matched cohort study
3个月前
已完结
Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study
3个月前
已完结
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
5个月前
已完结
IgG4-related disease: an update on pathophysiology and implications for clinical care
6个月前
已完结
Clinical Perspectives on IgG4-Related Disease and Its Classification
6个月前
已完结
Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
7个月前
已完结
Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset
8个月前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
8个月前
已完结
皖公网安备34019202002308
